Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.

about

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.

Item

http://www.wikidata.org/entity/Q47121756

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cost-effectiveness of enzyme r ...... t patients with Pompe disease.

@en

Cost-effectiveness of enzyme r ...... t patients with Pompe disease.

@nl

type

Item

label

Cost-effectiveness of enzyme r ...... t patients with Pompe disease.

@en

Cost-effectiveness of enzyme r ...... t patients with Pompe disease.

@nl

prefLabel

Cost-effectiveness of enzyme r ...... t patients with Pompe disease.

@en

Cost-effectiveness of enzyme r ...... t patients with Pompe disease.

@nl

P1476

Cost-effectiveness of enzyme r ...... t patients with Pompe disease.

@en

P2093

Ans T van der Ploeg

http://www.w3.org/2001/XMLSchema#string

Dimitris Rizopoulos

http://www.w3.org/2001/XMLSchema#string

Leona Hakkaart-van Roijen

http://www.w3.org/2001/XMLSchema#string

Maureen P M H Rutten-van Mӧlken

http://www.w3.org/2001/XMLSchema#string

Michelle E Kruijshaar

http://www.w3.org/2001/XMLSchema#string

W Ken Redekop

http://www.w3.org/2001/XMLSchema#string

P2860

The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review

208th ENMC International Workshop: Formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26-28 September 2014

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study

Orphan drugs and the NHS: should we value rarity?

EuroQol: the current state of play.

Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling.

A randomized study of alglucosidase alfa in late-onset Pompe's disease.

Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67

Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.

P2888

s13023-017-0731-0

P304

179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13023-017-0731-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tim A Kanters

P577

2017-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1099598111

http://www.w3.org/2001/XMLSchema#string

P698

29237491

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy

P932

5729274

http://www.w3.org/2001/XMLSchema#string